USO 24086

A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2) (CA0731022)

Disease Types: Lymphoma & Hematologic

Eligibility Requirements:

Histologically confirmed Grade 1, 2, or 3a FL or classic FL
• No prior therapy for disease
• Prior radiation or surgery for Stage I disease is
permitted
• ECOG ≤ 2. 3 is allowed if disease related and not due to
comorbidities
• Ann Arbor stage II-IV disease
• Subject must have indication requiring treatment,
determined by treating investigator
• Subjects with transformed lymphoma, follicular large cell or
Grade 3b follicular lymphoma are excluded
• Subjects with presence or history of CNS involvement by
lymphoma are excluded

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg